Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2022

View Archived Issues

NPC1L1 gene polymorphisms tied to coronary artery calcification

Novel series of glucosylceramide synthase inhibitors presented for treating Parkinson's disease

FDA clears IND for BiOneCure's anti-Trop-2 ADC, BIO-106

BETR-001 shows antidepressant activity in preclinical models

NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in models of HF

Discovery of noncovalent peptidomimetic proteasome inhibitors for the treatment of MM

Alternate approach could enable earlier detection, intervention, in Alzheimer's

HitGen and Uppthera extend their PROTAC collaboration

Harbour BioMed and AstraZeneca enter global outlicense agreement for HBM-7022

T cell-intrinsic AR activity drives IFN-gamma suppression and immunotherapy resistance

Peptidomimetic TMPRSS2 inhibitor shows prophylactic and therapeutic activity against SARS-CoV-2 VOCs

Medshine Discovery patents new sGC activators

Sunshine Lake Pharma discloses thyroid hormone receptor beta agonists

Aurigene Discovery Technologies presents CREBBP and/or KAT3B inhibitors

Merck & Co. synthesizes new GLCT-1 inhibitors

New TYK2 inhibitors identified by Esker Therapeutics

Emergex collaborates with nonprofit organization to advance yellow fever booster vaccine candidate

IKZF1 gain-of-function variants tied to T/B cell-related immune dysregulation

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...